TY - JOUR
T1 - Integrated myocardial flow reserve (iMFR) assessment
T2 - optimized PET blood flow quantification for diagnosis of coronary artery disease
AU - Poitrasson-Rivière, Alexis
AU - Moody, Jonathan B.
AU - Renaud, Jennifer M.
AU - Hagio, Tomoe
AU - Arida-Moody, Liliana
AU - Buckley, Christopher J.
AU - Al-Mallah, Mouaz H.
AU - Nallamothu, Brahmajee K.
AU - Weinberg, Richard L.
AU - Ficaro, Edward P.
AU - Murthy, Venkatesh L.
N1 - Funding Information:
The authors thank R.A. deKemp (Ottawa Heart Institute) for providing CFC thresholds appropriate for the 1-tissue-compartment kinetic model. The authors acknowledge the Regents of the University of Michigan for the use of de-identified clinical data for this study. The authors acknowledge GE for the use of de-identified data from the Flurpiridaz 301 trial (NCT01347710) data for this study.
Funding Information:
APR, JBM, JMR, and TH are employees of INVIA. JMR is a consultant for Jubilant Radiopharma and receives royalties from licensing of the FlowQuant software. EPF is a stockholder in INVIA. VLM has received research grants and speaking honoraria from Siemens Medical Imaging and serves as a scientific advisor for Ionetix and owns stock options in the same. He owns stock in GE and Cardinal Health, has received expert witness payments on behalf of Jubilant Radiopharma and a speaking honorarium from 2Quart Medical, and receives consulting payments and research support from INVIA. He is also supported by grants R01AG059729 from the National Institute on Aging, U01DK123013 from the National Institute of Diabetes and Digestive and Kidney Disease, and R01HL136685 from the National Heart, Lung, and Blood Institute.
Publisher Copyright:
© 2023, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2023/12
Y1 - 2023/12
N2 - Purpose: Distinguishing obstructive epicardial coronary artery disease (CAD) from microvascular dysfunction and diffuse atherosclerosis would be of immense benefit clinically. However, quantitative measures of absolute myocardial blood flow (MBF) integrate the effects of focal epicardial stenosis, diffuse atherosclerosis, and microvascular dysfunction. In this study, MFR and relative perfusion quantification were combined to create integrated MFR (iMFR) which was evaluated using data from a large clinical registry and an international multi-center trial and validated against invasive coronary angiography (ICA). Methods: This study included 1,044 clinical patients referred for 82Rb rest/stress positron emission tomography myocardial perfusion imaging and ICA, along with 231 patients from the Flurpiridaz 301 trial (clinicaltrials.gov NCT01347710). MFR and relative perfusion quantification were combined to create an iMFR map. The incremental value of iMFR was evaluated for diagnosis of obstructive stenosis, adjusted for patient demographics and pre-test probability of CAD. Models for high-risk anatomy (left main or three-vessel disease) were also constructed. Results: iMFR parameters of focally impaired perfusion resulted in best fitting diagnostic models. Receiver-operating characteristic analysis showed a slight improvement compared to standard quantitative perfusion approaches (AUC 0.824 vs. 0.809). Focally impaired perfusion was also associated with high-risk CAD anatomy (OR 1.40 for extent, and OR 2.40 for decreasing mean MFR). Diffusely impaired perfusion was associated with lower likelihood of obstructive CAD, and, in the absence of transient ischemic dilation (TID), with lower likelihood of high-risk CAD anatomy. Conclusions: Focally impaired perfusion extent derived from iMFR assessment is a powerful incremental predictor of obstructive CAD while diffusely impaired perfusion extent can help rule out obstructive and high-risk CAD in the absence of TID.
AB - Purpose: Distinguishing obstructive epicardial coronary artery disease (CAD) from microvascular dysfunction and diffuse atherosclerosis would be of immense benefit clinically. However, quantitative measures of absolute myocardial blood flow (MBF) integrate the effects of focal epicardial stenosis, diffuse atherosclerosis, and microvascular dysfunction. In this study, MFR and relative perfusion quantification were combined to create integrated MFR (iMFR) which was evaluated using data from a large clinical registry and an international multi-center trial and validated against invasive coronary angiography (ICA). Methods: This study included 1,044 clinical patients referred for 82Rb rest/stress positron emission tomography myocardial perfusion imaging and ICA, along with 231 patients from the Flurpiridaz 301 trial (clinicaltrials.gov NCT01347710). MFR and relative perfusion quantification were combined to create an iMFR map. The incremental value of iMFR was evaluated for diagnosis of obstructive stenosis, adjusted for patient demographics and pre-test probability of CAD. Models for high-risk anatomy (left main or three-vessel disease) were also constructed. Results: iMFR parameters of focally impaired perfusion resulted in best fitting diagnostic models. Receiver-operating characteristic analysis showed a slight improvement compared to standard quantitative perfusion approaches (AUC 0.824 vs. 0.809). Focally impaired perfusion was also associated with high-risk CAD anatomy (OR 1.40 for extent, and OR 2.40 for decreasing mean MFR). Diffusely impaired perfusion was associated with lower likelihood of obstructive CAD, and, in the absence of transient ischemic dilation (TID), with lower likelihood of high-risk CAD anatomy. Conclusions: Focally impaired perfusion extent derived from iMFR assessment is a powerful incremental predictor of obstructive CAD while diffusely impaired perfusion extent can help rule out obstructive and high-risk CAD in the absence of TID.
KW - Coronary artery disease
KW - Myocardial flow reserve
KW - Positron emission tomography
KW - Coronary Circulation
KW - Myocardial Perfusion Imaging/methods
KW - Constriction, Pathologic
KW - Humans
KW - Clinical Trials as Topic
KW - Coronary Artery Disease/diagnostic imaging
KW - Fractional Flow Reserve, Myocardial
KW - Multicenter Studies as Topic
KW - Atherosclerosis
KW - Coronary Angiography/methods
KW - Positron-Emission Tomography/methods
UR - http://www.scopus.com/inward/record.url?scp=85173103272&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85173103272&partnerID=8YFLogxK
U2 - 10.1007/s00259-023-06455-2
DO - 10.1007/s00259-023-06455-2
M3 - Article
C2 - 37807004
AN - SCOPUS:85173103272
SN - 1619-7070
VL - 51
SP - 136
EP - 146
JO - European Journal of Nuclear Medicine and Molecular Imaging
JF - European Journal of Nuclear Medicine and Molecular Imaging
IS - 1
ER -